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Abstract
Background: Apart from their well-known peripheral cardiovascular effects, emerging evidence indicates
that estrogen acts as a modulator in the brain to regulate cardiovascular functions. The underlying
mechanisms of estrogen in central cardiovascular regulation, however, are poorly understood. The
present study investigated the cardiovascular effects of 17β-estradiol (E2β) in the rostral ventrolateral
medulla (RVLM), where sympathetic premotor neurons are located, and delineated the engagement of
nitric oxide (NO) in E2β-induced cardiovascular responses.
Methods: In male Sprague-Dawley rats maintained under propofol anesthesia, the changes of blood
pressure, heart rate and sympathetic vasomotor tone after microinjection bilaterally into the RVLM of a
synthetic estrogen, E2β were examined for at least 120 min. The involvement of ERα and/or ERβ subtypes
was determined by microinjection of selective ERα or ERβ agonist into bilateral RVLM. Different NO
synthase (NOS) inhibitors were used to evaluate the involvement of differential of NOS isoforms in the
cardiovascular effects of E2β.
Results: Bilateral microinjection of E2β (0.5, 1, or 5 pmol) into the RVLM dose-dependently decreased
systemic arterial pressure (SAP) and the power density of the vasomotor components of SAP signals, our
experimental index for sympathetic neurogenic vasomotor tone. These cardiovascular depressive effects
of E2β (1 pmol) were abolished by co-injection of ER antagonist ICI 182780 (0.25 or 0.5 pmol), but not a
transcription inhibitor actinomycin D (10 nmol). Like E2β, microinjection bilaterally into the RVLM of a
selective ERβ agonist 2,3-bis(4-hydroxyphenyl) propionitrile (DPN, 1, 2, or 5 pmol) induced significant
decreases in these hemodynamic parameters in a dose-dependent manner. In contrast, the selective ERα
agonist 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole  (5 pmol) did not influence the same
cardiovascular parameters. Co-administration bilaterally into the RVLM of NOS inhibitor NG-nitro-L-
arginine methyl ester (5 nmol) or selective inducible NOS (iNOS) inhibitor S-methylisothiourea (25 pmol),
but not selective neuronal NOS inhibitor 7-nitroindazole (0.5 pmol) or endothelial NOS inhibitor N5-(1-
Iminoethyl)-L-ornithine (2.5 pmol), significantly attenuated the cardiovascular depressive effects elicited by
DPN (2 pmol).
Conclusion: Our results indicate that E2β in the RVLM elicited short-term cardiovascular depressive
effects via an ERβ-dependent nontranscriptional mechanism. These vasodepressor effects of E2β are likely
to be mediated by the iNOS-derived NO in the RVLM.
Published: 7 July 2009
Journal of Biomedical Science 2009, 16:60 doi:10.1186/1423-0127-16-60
Received: 16 May 2009
Accepted: 7 July 2009
This article is available from: http://www.jbiomedsci.com/content/16/1/60
© 2009 Shih; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The cost of publication in Journal of Biomedical Science
is bourne by the National Science Council, Taiwan.Journal of Biomedical Science 2009, 16:60 http://www.jbiomedsci.com/content/16/1/60
Page 2 of 9
(page number not for citation purposes)
Background
Most known biological effects of estrogen, a major female
gonadal steroid, are mediated by binding of the hormone
to estrogen receptor (ER) subtypes, ERα and ERβ [1]. The
ERs belong to a member of the nuclear hormone family of
intracellular receptors that function as ligand-dependent
transcriptional coactivators [1]. Upon binding to nuclear
ERs, estrogen and ER forms a complex to bind at specific
response elements in the promoters of target genes where
it regulates gene transcription through direct interactions
with DNA or other transcriptional machinery proteins
[1,2]. This transcriptional mode of action is responsible
for the well defined, long-lasting cellular responses of
estrogen.
Recent studies have demonstrated that activated ER may
promote physiological functions via nontranscriptional
mechanisms [1,3,4]. In the heart and vasculature, the
nongenomic mechanisms underlie estrogen-induced
short-term arterial vasodilation [4,5], inhibition of
atherosclerotic lesions [4,6] and amelioration of
ischemia/reperfusion-induced cardiac injury [7]. These
estrogen-triggered rapid cardiovascular responses are
thought to be mediated via direct activation by the hor-
mone of the cellular membrane rather than intracellular
receptors [3,4,8].
Apart from their well-known peripheral cardiovascular
effects, emerging evidence indicates that estrogen acts as a
modulator in the brain to regulate cardiovascular func-
tions [9-14]. Intracerebroventricular injection of estrogen
increases systemic arterial pressure (SAP) and sympathetic
nerve activity in female rats [9]. In estrogen-replaced ova-
riectomized female rats [12], but not in male rats [11],
peripheral injection of estrogen decreases baseline sympa-
thetic tone and SAP, which are antagonized by central
injection of the selective ER antagonist [11,12]. Within
the brain stem, both ER mRNA [15] and protein [16,17]
are distributed in neurons of the rostral ventrolateral
medulla (RVLM), where sympathetic premotor neurons
for the maintenance of basal vasomotor tone are located
[18], making this nucleus a candidate substrate to sub-
serve the central cardiovascular regulatory actions of estro-
gen. Only a few studies [13,14] reported the
cardiovascular regulatory actions of estrogen in the RVLM.
Moreover, the underlying mechanisms mediating central
cardiovascular effects of estrogen are not fully understood.
The present study was therefore undertaken to evaluate
the hypothesis that estrogen in the RVLM participates in
neural regulation of cardiovascular functions via ERβ-
dependent mechanisms that entail activation of nitric
oxide (NO) signaling.
Methods
Animals
Experiments were carried out in adult male Sprague-Daw-
ley rats (250–300 g, n = 126) purchased from the Experi-
mental Animal Center of the National Science Council
(Taipei, Taiwan). The male rats were chosen in this study
to avoid possible confounding influence from differing
circulating estrogen levels in cycling female rats. All rats
were kept under conditions of constant temperature (23 ±
0.5°C) with a standard 12 h light-dark cycle (08:00–
20:00) and free access to standard laboratory rat chow
(Purina) and tap water. They were allowed to acclimatize
for at least 7 days before experimental manipulations. All
experiment procedures were conducted in compliance
with the guidelines of our institutional animal care com-
mittee. All efforts were made to reduce the numbers of
animals used and to minimize animal suffering during
the experiment.
General animal preparation
The preparatory surgery including intubation of the tra-
chea and cannulation of the femoral artery and both fem-
oral veins was performed under an induction dose of
pentobarbital sodium (50 mg/kg, i.p.) [19,20]. During
recording session, the anesthetic maintenance of the ani-
mals was achieved by an intravenous infusion of propofol
(Zeneca Pharmaceuticals, Macclesfield, UK) at 20–30 mg/
kg/h. This management scheme [21] provides satisfactory
anesthetic maintenance while preserving the capacity of
neural control of cardiovascular functions. The same man-
agement scheme also has no significant effect in increas-
ing respiratory resistance [22] or airway mucus secretion
[23]. Animals also received neuromuscular blockade with
intravenous infusion of pancuronium (2 mg/kg/h) via the
femoral vein. Pulsatile and mean SAP (MSAP), as well as
heart rate (HR), was recorded on a polygraph (Gould
RS3400, Valley View, OH, USA). Animals were ventilated
mechanically by the use of a small rodent ventilator (Har-
vard 683, South Natik, MA, USA) to maintain an end-tidal
CO2 within 4.0–4.5%, as monitored by a capnograph
(Datex Normocap, Helsinki, Finland). This procedure was
conducted to minimize possible confounding cardiovas-
cular changes secondary to respiratory perturbation. The
head of the animal was thereafter fixed to a stereotaxic
headholder (Kopf 1430, Tujunga, CA, USA), and the rest
of the body was placed on a thermostatically controlled
pad to maintain rectal temperature of 37 ± 0.5°C. All data
were collected from animals with a steady baseline MSAP
above 90 mmHg throughout the recording period.
Recording and power spectral analysis of SAP signals
The SAP signals recorded from the femoral artery were
simultaneously subject to on-line power spectral analysis
as detailed previously [21,24]. We were particularly inter-
ested in the very low-frequency (0–0.25 Hz) and low-fre-Journal of Biomedical Science 2009, 16:60 http://www.jbiomedsci.com/content/16/1/60
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quency (0.25–0.8 Hz) components of the SAP spectrum.
These spectral components of SAP signals were reported
to take origin from the RVLM [25] and their power density
reflect the prevailing sympathetic neurogenic vasomotor
tone [19-21,26]. The power densities of these two spectral
components were displayed during the experiment,
alongside SAP, MSAP and HR, in an online and real-time
manner.
Microinjection of test agents into the RVLM
Microinjection bilaterally of test agents into the function-
ally identified RVLM sites were performed stereotaxically
and sequentially with a glass micropipette (external tip
diameter: 50–80 μm) connected to a 0.5-μl Hamilton
microsyringe (Reno, NV, USA). A total volume of 50 nl
was delivered to each side over 1–2 min to allow for com-
plete diffusion of the injected solution. The time between
injections from one side of the RVLM to the other was 5–
6 min. The stereotaxic coordinates for the RVLM were 4.5
to 5.0 mm posterior to lambda, 1.8 to 2.1 mm lateral to
midline, and 8.0 to 8.5 mm below the dorsal surface of
the cerebellum. These coordinates were selected to cover
the ventrolateral medulla in which both ER mRNA [15]
and protein [16,17] are distributed, and where function-
ally identified sympathetic premotor neurons are located
[18].
At the beginning of each experiment, the functional loca-
tion of RVLM neurons on either side was established by
monitoring a transient pressor response (15–25 mmHg)
after microinjection of L-glutamate (1 nmol, Sigma
Chemical). Subsequent microinjections of test agents
were delivered to the identified pressor loci 20 min after
the completion of glutamate application. This time lag
was introduced to ensure complete recovery from the
glutamate-induced pressor response before microinjec-
tion bilaterally into the RVLM of test agents or vehicle.
All microinjection solutions contained 1% Evans blue to
aid in subsequent histological verification of the injection
site. Possible volume effect of microinjection was control-
led by injecting the same amount of artificial cerebrospi-
nal fluid (aCSF, pH 7.4) of the following composition (in
mM): 126 NaCl, 2.5 KCl, 2 CaCl2, 1–2 MgCl2, 1.25
NaH2PO4, 26 NaHCO3, and 10 D-glucose. To avoid con-
founding effects of drug interactions, each animal
received only one treatment of synthetic estrogen, selec-
tive ERα, ERβ agonist or vehicle, given alone or in combi-
nation with one test agent.
Preparation of test agents
The test agents were used in this study included 17β-estra-
diol-3-sulphate sodium (E2β; Sigma-Aldrich, St. Louis,
MO, USA); a selective ERα agonist, 1,3,5-tris(4-hydroxy-
phenyl)-4-propyl-1H-pyrazole (PPT; Tocris Cookson Inc.,
Bristol, UK); a selective ERβ agonist, 2,3-bis(4-hydroxy-
phenyl) propionitrile (DPN; Tocris Cookson); 17α-estra-
diol (E2α; Sigma-Aldrich); a nonspecific ER antagonist,
ICI 182780 (Tocris Cookson); a selective ERα antagonist,
methyl-piperidino-pyrazole (MPP; Tocris Cookson); a
selective ERβ antagonist, R,R-tetrahydrochrysene (R,R-
THC; Tocris Cookson); a nonselective NO synthase
(NOS) inhibitor, NG-nitro-L-arginine methyl ester (L-
NAME; Sigma-Aldrich); a selective inducible NOS (iNOS)
inhibitor, S-methylisothiourea (SMT; Tocris Cookson); a
selective neuronal NOS (nNOS) inhibitor, 7-nitroinda-
zole (7-NI; Tocris Cookson); a selective endothelial NOS
(eNOS) inhibitor, N5-(1-Iminoethyl)-L-ornithine (L-
NIO; Tocris Cookson); or a transcription inhibitor, actin-
omycin D (AMD; Tocris Cookson). The dose and treat-
ment scheme were adopted from our preliminary
experiments and previous studies [20,26], which used the
same test agents for the same purpose as in this study.
Moreover, to avoid confounding cardiovascular effects
evoked by individual test agent, we purposely selected
dose that did not alter the baseline circulatory parameters
when microinjected alone into the bilateral RVLM. The
dose of each antagonist or inhibitor used in this study,
nonetheless, has been shown in our pilot studies to signif-
icantly inhibit cardiovascular responses induced by its
specific ligand. All test agents were dissolved in aCSF at
pH 7.4, with the exception of ICI 182780 and 7-NI, which
used, respectively, 5% dimethyl sulfoxide (DMSO) or 3%
methanol as the solvent. Control experiments showed
that these vehicles had no significant effect on baseline
MSAP or HR during the 120 min observation period.
Brain histology
At the conclusion of each experiment, the animal was
killed by an overdose of pentobarbital sodium, and the
brain stem was removed from animals and fixed in 30%
sucrose in 10% formaldehyde-saline solution for at least
72 h. Histological verification of the location of microin-
jection sites was carried out on frozen 25-μm sections of
the medulla oblongata stained with 1% Neutral red.
Statistical analysis
All values are expressed as mean ± SEM. The two-way anal-
ysis of variance (ANOVA) with repeated measures was
used to assess group difference in the effect of various
treatments on time course of changes in MSAP, HR or
power density of vasomotor components of SAP spec-
trum. This was followed by the Scheffé multiple-range test
for post hoc assessment of individual means. The maximal
changes in the hemodynamic parameters were evaluated
with paired t-test. P < 0.05 was considered statistically sig-
nificant.Journal of Biomedical Science 2009, 16:60 http://www.jbiomedsci.com/content/16/1/60
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Results
Cardiovascular effects of microinjection bilaterally into 
the RVLM of E2β
Compared to aCSF treatment, microinjection bilaterally
into the functionally identified pressor region of RVLM of
E2β (0.5, 1, or 5 pmol) resulted in significant and dose-
dependent decreases in MSAP and power density of vaso-
motor components of SAP spectrum, our experimental
index for sympathetic neurogenic vasomotor outflow [19-
21,24], without apparent effect on HR (Fig. 1). The cardi-
ovascular depressive responses of E2β commenced
approximately 30 min, and lasted for at least 120 min
posttreatment. Duration of cardiovascular depressive
responses of E2β (0.5, 1, or 5 pmol) was dose dependent.
At a lower dose (0.5 pmol), E2β promoted vasodepressor
responses that lasted for approximately 150 min postin-
jection, whereas at higher doses (1 or 5 pmol) E2β pro-
duced cardiovascular depressive responses that sustained
more than 3–4 hrs postinjection. Microinjection bilater-
ally into the RVLM of the inactive isomer of estrogen, E2α
(5 pmol), on the other hand, did not affect basal hemody-
namic parameters (Fig. 1). Microinjection of E2β (5
pmol) into the ventrolateral medullary areas adjacent to,
but outside the confine of RVLM, e.g., spinal trigeminal
nucleus or lateral paragigantocellular nucleus, also elic-
ited minimal effects on those cardiovascular parameters
(data not shown). In addition, intravenous injection of a
high dose (5 pmol) E2β did not affect baseline MSAP, HR
or power density of vasomotor components of SAP spec-
trum (MSAP: -3.2 ± 1.6 mmHg; HR: +4.3 ± 0.8 bpm; SAP
spectrum: -0.6 ± 0.5 mmHg2, n = 3).
Effects of ER antagonist on the E2β-induced 
cardiovascular depressive responses
Co-administration bilaterally into the RVLM of a nonspe-
cific ER antagonist, ICI 182780 (0.25 or 0.5 pmol) atten-
uated the cardiovascular depressive responses of E2β (1
pmol) (Fig. 2) in a dose-related manner. At high dose (0.5
pmol), ICI 182780 almost completely reversed the E2β-
induced hypotension and the decrease in sympathetic vas-
omotor tone. Comparable results were obtained in ani-
mals that received ICI 182780 delivered at 20 min before
E2β microinjection (data not shown). In addition, co-
administration bilaterally into the RVLM of a specific ERβ
antagonist R,R-THC (50 pmol), but not a specific ERα
antagonist MPP (1 nmol), attenuated the vasodepressor
responses induced by E2β (1 pmol) (maximal decrease in
MSAP: E2β alone: -48.6 ± 6.3 mmHg vs. E2β+R,R-THC: -
18 ± 6.1 mmHg, n = 4, P < 0.05; maximal decrease in
MSAP: E2β alone: -48.6 ± 6.3 mmHg vs. E2β+MPP: -50.3
± 5.4 mmHg, n = 4, P > 0.05). Microinjection bilaterally
into the RVLM of ICI 182780 (0.25 or 0.5 pmol), R,R-THC
(50 pmol) or MPP (1 nmol) alone, on the other hand, had
no discernible effect on baseline MSAP, HR or power den-
sity of vasomotor components of SAP spectrum (Table 1).
In contrast, co-administration bilaterally into the RVLM of
a transcription inhibitor AMD (10 nmol), did not affect
the cardiovascular depressive response of E2β (1 pmol)
(maximal decrease in MSAP: E2β alone: -46.8 ± 5.3
mmHg vs. E2β+AMD: -52 ± 6.5 mmHg, n = 6, P > 0.05).
Cardiovascular effects after microinjection bilaterally into the  RVLM of E2β Figure 1
Cardiovascular effects after microinjection bilaterally 
into the RVLM of E2β. Time-course of the changes in 
mean systemic arterial pressure (MSAP), heart rate (HR) and 
total power density of vasomotor components (0–0.8 Hz) of 
systemic arterial pressure (SAP) spectrum in anaesthetized 
rats that received microinjection bilaterally into the rostral 
ventrolateral medulla (RVLM, at time 0) of artificial cerebros-
pinal fluid (aCSF), 17β-estradiol (E2β, 0.5, 1 or 5 pmol), or 
17α-estradiol (E2α, 5 pmol). Values are presented as mean ± 
S.E.M., n = 6–8 animals per experimental group. *P < 0.05 
versus corresponding aCSF group in the Scheffé multiple 
range test.Journal of Biomedical Science 2009, 16:60 http://www.jbiomedsci.com/content/16/1/60
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Cardiovascular effects of microinjection bilaterally into 
the RVLM of ERα or ERβ agonist
To decipher the role of ERα and/or ERβ subtypes in E2β-
induced cardiovascular depressive responses, we evalu-
ated the cardiovascular effects of the selective ERα or ERβ
agonist in the RVLM. Similar to effects induced by E2β,
microinjection bilaterally into the RVLM of ERβ agonist
DPN (1, 2 or 5 pmol) promoted hypotension and reduc-
tion in sympathetic vasomotor tone in a dose-related
manner (Fig. 3). In contrast, the same doses of DPN (2 or
5 pmol) microinjected outside the confine of RVLM (e.g.,
spinal trigeminal nucleus or lateral paragigantocellular
nucleus) caused a minimal alteration in the same cardio-
vascular parameters (data not shown). In a separate series
of experiments, microinjection bilaterally into the RVLM
of ERα agonist PPT (5 pmol) did not affect basal hemody-
namic parameters (Fig. 3). Similarly, intravenous injec-
tion of DPN (5 pmol) did not affect the baseline MSAP,
HR or power density of vasomotor components of SAP
spectrum (MSAP: -4.1 ± 1.2 mmHg; HR: +4.4 ± 1.1 bpm;
SAP spectrum: -0.7 ± 0.5 mmHg2, n = 3).
Effects of NOS inhibitor on the ERβ agonist-induced 
cardiovascular depressive effects
Compared with the aCSF or 3% MeOH controls, co-
administration of the nonselective NOS inhibitor, L-
NAME (5 nmol) significantly attenuated hypotension and
reduction in power density of vasomotor components of
SAP spectrum promoted by microinjection bilaterally into
the RVLM of DPN (2 pmol) (Fig. 4). Of the three isoforms
of NOS, we found that only the iNOS inhibitor SMT (25
pmol), but not the nNOS inhibitor 7-NI (0.5 pmol) or the
eNOS inhibitor L-NIO (2.5 pmol), appreciably attenuated
the DPN-induced cardiovascular depressive responses
(Fig. 4). Microinjection into bilateral RVLM of L-NAME (5
nmol), SMT (25 pmol), 7-NI (0.5 pmol), or L-NIO (2.5
pmol) alone had no significant effect on baseline MSAP,
HR or power density of vasomotor components of SAP
spectrum (Table 1).
Effects of ER antagonist on the E2β-induced cardiovascular  depressive responses Figure 2
Effects of ER antagonist on the E2β-induced cardio-
vascular depressive responses. Time-course of the 
changes in MSAP and total power density of vasomotor com-
ponents (0–0.8 Hz) of SAP spectrum in anaesthetized rats 
that received microinjection bilaterally into the RVLM (at 
time 0) of aCSF, or E2β (1 pmol) given together with ICI 
182780 (ICI, 0.25 or 0.5 pmol) or 5% DMSO. Values are pre-
sented as mean ± S.E.M., n = 6–8 animals per experimental 
group. *P < 0.05 versus corresponding aCSF group, and #P < 
0.05 versus corresponding E2β+DMSO group in the Scheffé 
multiple range test.
Table 1: Effects of test agents on baseline MSAP, HR and power density of vasomotor components of SAP spectrum
Treatment Maximal changes in
MSAP (mmHg) HR (bpm) Power Density (mmHg2)
aCSF +3.3 ± 0.4 +4.9 ± 0.6 +0.7 ± 0.5
ICI 182780 (0.25 pmol) +3.3 ± 0.6 +5.5 ± 0.8 +0.7 ± 0.5
ICI 182780 (0.5 pmol) +2.5 ± 0.5 +3.5 ± 0.8 +0.6 ± 0.6
R,R-THC (50 pmol) +6.4 ± 0.6 +6.5 ± 1.0 +0.8 ± 0.4
MPP (1 nmol) +6.1 ± 0.8 +6.6 ± 0.8 +0.9 ± 0.7
L-NAME (5 nmol) +3.8 ± 0.6 +5.6 ± 0.6 +0.9 ± 0.6
SMT (25 pmol) +3.7 ± 0.8 +5.3 ± 0.8 +0.7 ± 0.5
7-NI (0.5 pmol) -2.7 ± 0.8 -3.3 ± 0.5 -0.6 ± 0.8
L-NIO (2.5 pmol) -1.9 ± 0.8 -3.6 ± 0.7 -1.0 ± 0.6
Values are mean ± S.E.M., n = 6–7 animals per experimental group. No significant difference was detected among groups in the paired t-test.Journal of Biomedical Science 2009, 16:60 http://www.jbiomedsci.com/content/16/1/60
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Microinjection sites
Histological verification of locations of micropipette tips
in the ventrolateral medulla confirmed that all observa-
tions were made from animals that received local admin-
istration of the test agents within the anatomic confines of
the RVLM (Fig. 5). For the purpose of clarity, Fig. 5 only
summarizes the location of sites where microinjection of
E2β (5 pmol) and DPN (5 pmol) elicited significant (P <
0.05) inhibitory effects on the MSAP and power density of
vasomotor components of SAP spectrum.
Discussion
To the best of our knowledge, the present study is the first
demonstration of an active role of ERβ at the RVLM in cen-
tral cardiovascular regulation. We found that E2β and ERβ
agonist dose-dependently decreased MSAP and power
density of vasomotor components of SAP spectrum,
whereas ERα agonist did not change these hemodynamic
parameters. We further demonstrated that the iNOS-
derived NO in the RVLM is involved in the ERβ-depend-
ent cardiovascular depressive effects.
Accumulative evidence indicates estrogen as an active hor-
mone in central cardiovascular regulation [9-14] via acti-
vation of the ERα and ERβ [1]. Within the brain stem, ERα
and ERβ mRNA [15] as well as protein [16,17]are
Cardiovascular effects after microinjection bilaterally into the  RVLM of ERα or ERβ agonist Figure 3
Cardiovascular effects after microinjection bilaterally 
into the RVLM of ERα or ERβ agonist. Time-course of 
the changes in MSAP, HR and total power density of vasomo-
tor components (0–0.8 Hz) of SAP spectrum in anaesthetized 
rats that received microinjection bilaterally into the RVLM 
(at time 0) of aCSF, DPN (1, 2 or 5 pmol), or PPT (5 pmol). 
Values are presented as mean ± S.E.M., n = 6–8 animals per 
experimental group. *P < 0.05 versus corresponding aCSF 
group in the Scheffé multiple range test.
Effects of NOS inhibitor on the ERβ agonist-induced cardio- vascular depressive effects Figure 4
Effects of NOS inhibitor on the ERβ agonist-induced 
cardiovascular depressive effects. Time-course of the 
changes in MSAP and total power density of vasomotor com-
ponents (0–0.8 Hz) of SAP spectrum in anaesthetized rats 
that received microinjection bilaterally into the RVLM (at 
time 0) of aCSF, 3% methanol (MeOH), or DPN (2 pmol) 
given together with L-NAME (5 nmol), SMT (25 pmol), 7-NI 
(0.5 pmol), L-NIO (2.5 pmol) or 3% MeOH. Values are mean 
± S.E.M., n = 6–7 animals per experimental group. *P < 0.05 
versus corresponding MeOH group, and #P < 0.05 versus 
corresponding DPN+MeOH group in the Scheffé multiple 
range test. Data on aCSF are not shown because they in 
essence duplicated those by 3% MeOH.Journal of Biomedical Science 2009, 16:60 http://www.jbiomedsci.com/content/16/1/60
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expressed in the RVLM. Function of these RVLM neurons
expressing ERs, however, is not fully understood. One
major finding of the present study is the identification of
a short-term vasodepressor effect of estrogen in the RVLM.
A lower dose (0.5 pmol) of E2β promoted acute vasode-
pressor responses that lasted for 150 min postinjection,
whereas at higher doses (1 or 5 pmol) E2β produced sim-
ilar effects that sustained more than 3–4 hrs postinjection.
It has been reported that direct microinjection of the same
steroid hormone (0.5 μM) into the RVLM produces a
short-term (<60 min) hypotension [13]. These results sug-
gest that the duration of short-term vasodepressor effects
of E2β in the RVLM is manifested in a dose-dependent
manner. Long-term (>24 hrs) cardiovascular effect of E2β
in the RVLM and the involvement of nongenomic and/or
genomic signaling mechanisms, however, await further
investigation. In addition, we demonstrated that these
cardiovascular regulatory effects of the female steroids are
nucleus specific, since application of E2β or its agonist,
DPN, to areas outside the confines of the RVLM did not
influence the baseline hemodynamics. More importantly,
we found that high dose E2β or DPN promoted cardiovas-
cular depression only when they were microinjected into
the bilateral RVLM but not intravenously. These findings
confirmed that the E2β- and DPN-induced cardiovascular
depressive responses are not caused by leakage of these
test agents from the injection site in the brain to the
peripheral circulation.
There are only a limited data from in vivo studies to dem-
onstrate the role of estrogen in central cardiovascular reg-
ulation. Consistent with our observation, a previous study
[13] reported that direct microinjection of E2β into the
RVLM elicits significant decreases in SAP and sympathetic
nerve activity in male rats, suggesting that estrogen partic-
ipate in central cardiovascular regulation by acting
directly on the RVLM. At receptor level, we found that the
cardiovascular depressive effects of E2β are mediated via
activation of the ERβ in the RVLM. The nonselective ER
antagonist ICI 182780, at the dose that did not by itself
alter the baseline circulatory parameters implying that
endogenous estrogen may not exerts a tonic effect on the
cardiovascular responses at the level of the RVLM, whereas
this antagonist almost completely reversed the cardiovas-
cular depressive effects by E2β. Furthermore, we also dem-
onstrate that the cardiovascular depressive effects induced
by selective ERβ agonist DPN, but not the selective ERα
agonist PPT, are similar to that induced by E2β. We also
employed specific ERα or ERβ antagonist to demonstrate
engagement of ERβ but not ERα in the E2β-mediated
vasodepressor effects in the RVLM. These results suggest
that E2β in the RVLM induces vasodepressor effects
mainly via the ERβ-mediated mechanisms. This sugges-
tion is supported by the study that in the isolated RVLM
neurons, E2β possesses rapid inhibitory effect on the volt-
age-gated Ca++ currents, which is mimicked by the ERβ-
selective but not the ERα-selective agonist [17]. Addition-
ally, ERβ knockout mice exhibit sustained hypertension
and abnormal vascular function indicating an essential
role for ERβ in the regulation of vascular function and
blood pressure [27]. Anatomically, the distribution of
ERβ-immunoreactivity in the RVLM neurons is prominent
in the extra-nuclear sites than that of ERα, particularly on
plasma membranes [17]. The observed short-term hypo-
tension and reduction in sympathetic vasomotor tone,
which occurred approximately 30 min after microinjec-
tion of E2β or ERβ agonist into the RVLM, may therefore
mediated by a nongenomic signaling mechanism. In sup-
port of this suggestion, we found that transcription inhib-
itor, AMD, did not affect the E2β-induced short-term
vasodepressor response. The rapid nongenomic actions of
Microinjection sites of E2β and DPN in the RVLM Figure 5
Microinjection sites of E2β and DPN in the RVLM. 
Diagrammatic representations of two rostral-caudal levels of 
the RVLM (dotted line areas) with reference to the lambda 
illustrating the location of sites where bilateral microinjection 
of E2β (black circle, 5 pmol) and DPN (,5 pmol) elicited sig-
nificant inhibitory or minimal effects (black square, non-
RVLM microinjection sites) on the MSAP and power density 
of vasomotor components of SAP spectrum. Numbers on 
right side indicate distance from the lambda. For the purpose 
of clarity, approximately 20% of the total microinjection sites 
are included and are presented on both side of the diagram. 
ION, inferior olivary nucleus; NA, nucleus ambiguous; NTS, 
nucleus tractus solitarii; RVLM, rostral ventrolateral medulla; 
V, nucleus of the spinal trigeminal nerve; py, pyramidal tract.Journal of Biomedical Science 2009, 16:60 http://www.jbiomedsci.com/content/16/1/60
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estrogen in both cardiac [7,28] and vascular [4,5] systems
are mediated directly by ERs located in or close to the cel-
lular membrane rather than the nuclear sites [3,4,8]. Cel-
lular mechanism underling the ERβ-mediated short-term
cardiovascular effect in the RVLM, however, awaits further
investigation.
Another major contribution of this study is to demon-
strate the involvement of NO in cardiovascular depression
induced by activation of ERβ in the RVLM. NO is a well-
established neuromodulator for central cardiovascular
regulation in the RVLM [26,29-34]. Microinjection of the
NO precursor or donor into the RVLM reportedly pro-
duces prominent depressor effects and reduced sympa-
thetic nerve activity [26,29-31]. In the present study we
found that the ERβ agonist-induced cardiovascular
depressive responses were attenuated by co-administra-
tion of the nonselective NOS inhibitor, L-NAME. These
results indicate that NO is engaged in cardiovascular
depression induced by activation of ERβ and further
imply that cardiovascular depressive responses of estrogen
may be mediated via an interaction between estrogen and
NO signals in the RVLM. This suggestion is supported by
the study that estrogen alters the NOS expression via acti-
vation of ERβ in the hypothalamic paraventricular
nucleus [35]. In addition, estrogen replacement in ova-
riectomized rats reduces arterial pressure responses to psy-
chological stress by increasing NO production in brain
stem and hypothalamus [36]. Intracarotid injection of
estrogen inhibits spontaneous electrical activity of RVLM
neurons via the activation of NO-dependent signaling
pathway [37]. Of the three isoforms of NOS that have
been identified in the RVLM, we found that NO derived
from iNOS may play a major role in the ERβ-dependent
cardiovascular depression. The iNOS-derived NO in the
RVLM has been reported to elicit sympathoinhibition and
vasodepressor effects [26,33,34]. A negative result of 7-NI
or L-NIO, on the other hand, implies a minor role of
nNOS and eNOS in the ERβ-dependent cardiovascular
depression in the RVLM. At a lower dose than those used
in the present study, 7-NI or L-NIO has been reported to
selective inhibit the nNOS-derived NO in the hypotha-
lamic paraventricular nucleus [38] or L-arginine-induced
NO synthesis in the vascular endothelium [39]. We noted
that L-NAME or iNOS inhibition did not completely
attenuate the cardiovascular depressive responses induced
by ERβ agonist. The involvement of NO-independent
alternative pathways in the cardiovascular depressive
effects of E2β in the RVLM, therefore, awaits further inves-
tigation.
To avoid confounding cardiovascular effects caused by
differing levels of circulating estrogen through various
stages in cycling female rats, we purposely selected male
animals in the present study. In addition, a number of
previous studies on the rapid cardiovascular effects of
estrogen in the RVLM [13] or other central autonomic
nuclei [13,40] were done in male rats. PPT and DPN are
reported to be a useful experimental tool to study the dif-
ferences in structure and biological functions of ERα and
ERβ [17,41,42]. The selectivity of nonsteroidal estrogen,
PPT and DPN as respective ERα and ERβ agonist has been
documented [17,41,42]. PPT and DPN exhibits a relative
high selectivity toward ERα and ERβ, respectively, when
compared with some phytoestrogens such as genistein
and coumestrol [43]. We also realize that this study was
conducted under an anesthetic condition that may be a
major confounding factor to the observed cardiovascular
responses. This possibility, however, is deem unlikely
since we demonstrated previously [19,20] that the anes-
thetic maintenance scheme (i.e., propofol at 20–30 mg/
kg/h) used in this study has no discernible effect on the
sympathetic vasomotor outflow from the RVLM, and
hence baseline MSAP and HR [21].
In conclusion, our results demonstrate that the E2β in the
RVLM elicited short-term non-genomic cardiovascular
inhibitory effects via activation of ERβ. Furthermore, NO
derived from iNOS may contribute to central vasodepres-
sor effects after activation of ERβ in the RVLM.
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